Imidazol-1-yl and Pyridin-3-yl Derivatives of 4-Phenyl-1,4-dihydropyridines Combining Ca2+ Antagonism and Thromboxane A2 Synthase Inhibition

Journal of Medicinal Chemistry

Volumn 36, Issue 20, 1993, Pages 2964-2972

  Cozzi, Paolo ^a   Carganico, Germano ^a,b   Fusar, Domenico ^a   Grassoni, Mauro ^a   Menichincheri, Maria ^a   Pinciroli, Vittorio ^a   Tonani, Roberto ^a   Vaghi, Fabrizio ^a   Salvati, Patricia ^a  

^a PFIZER INC   (United States)

^b Laboratorios Menarini   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 4 [3 (1H IMIDAZOL 1 YL)PHENYL] 2,6 DIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; FCE 24265; NIFEDIPINE; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CALCIUM ANTAGONISM; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG STRUCTURE; ENZYME INHIBITION; MALE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TACHYCARDIA;

ANIMAL; BLOOD PRESSURE; CALCIUM; COMPARATIVE STUDY; DIHYDROPYRIDINES; DOGS; GUINEA PIGS; ILEUM; IMIDAZOLES; MALE; MOLECULAR STRUCTURE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MYOCARDIAL CONTRACTION; NIFEDIPINE; POTASSIUM; PYRIDINES; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOXANE-A SYNTHASE;

EID: 0027428755     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00072a017     Document Type: Article

References (46)

1. Hansson, L. Calcium antagonists: An Overview. Am. Heart J. 1991, 122, 308–311 and references cited therein.
2. Pickard, J. D.; Murray, G. D.; Illingworth, R.; Shaw, M. D. M.; Teasdale, G. M.; Foy, P. M.; Humphrey, P. R. D.; Lang, D. A.; Nelson, R.; Richards, P.; Sinar, J.; Bailey, S.; Skene, A. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British aneurysm nimodipine trial. Brit. Med. J. 1989, 298, 636–642.
3. Buchbeit, J. M.; Tremoulet, M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysm. Neurosurg. 1988, 23, 164-157.
4. Loogna, E.; Sylven, C.; Groth, T.; Mogensen, L. Complexity of enzyme release during acute myocardial infarction in a controlled study with early nifedipine treatment. Eur. Heart J. 1985, 6, 114–119.
5. SPRINT Study Group. The secondary prevention re-infarction Israeli nifedipine trial (SPRINT) II: design and methods, results. Eur. Heart. J. 1988, 9 (Suppl. I), 350A.
6. Myocardial Infarction Study Group. Secondary prevention of ischemic heart disease: a long term controlled lidoflazine study. Acta Cardiol. 1979, 34 (Suppl. 24), 7–46.
7. Subramanian, V. B. Calcium Antagonists in Chronic Stable Angina Pectoris. Excerpta Medica (Amsterdam) 1983, 97–116.
8. Mueller, H. S.; Chahine, R. A. Interim report of multicenter double-blind, placebo controlled studies of nifedipine in chronic stable angina. Am. J. Med. 1981, 71, 646–657.
9. Antman, E.; Muller, J.; Goldberg, S.; McAlpin, R.; Rubenfire, M.; Tabatznik, B.; Liang, C.-S.; Heupier, F.; Achuff, S.; Reichek, N.; Geltman, E.; Kerin, N. Z.; Neff, R. K.; Braunwald, E. Nifedipine therapy for coronary artery spasm. Experience with 127 patients. N. Engl. J. Med. 1980, 302, 1269–1273.
10. Ginsburg, R.; Lamb, I. H.; Schroeder, J. S.; Harrison, M. H.; Harrison, D. C. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am. Heart. J. 1982, 103, 44–48.
11. Held, P. H.; Yusuf, S.; Furberg, C. D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br. Med. J. 1989, 299, 1187.
12. Reicher-Reiss, H.; Barasch, E. Calcium Antagonists in Patients with Heart Failure. Drugs 1991, 42(3), 343–364.
13. Gelmers, H. J.; Henneric, N. Effect of nimodipine on acute ischemic stroke: pooled results from five randomized trials. Stroke 1990, 21 (Suppl. IV), 81-IV84.
14. Di Bona, G. F.; Epstein, M.; Mann, J.; Nordlander, M. Renal Protective Aspects of Calcium Antagonists. Kidney Int. 1991, 41 (Suppl. 36).
15. Triggle, D. J. Calcium Antagonists and Atherosclerosis. Drugs Today 1991, 27(3), 147–155 and references cited therein.
16. Vesterqvist, O.; Edhag, O.; Green, K.; Henriksson, P. “In vivo” production of Thromboxane in acute human myocardial infarction: a preliminary study. Thrombosis Res. 1985, 37, 459–464.
17. Fitzgerald, D. J.; Roy, L.; Catella, F.; FitzGerald, G. A. Platelet activation in unstable coronary disease. N. Engl. J. Med. 1986, 315, 983–989.
18. Remuzzi, G.; FitzGerald, G. A.; Patrono, C. Thromboxane synthesis and action within the kidney. Kidney Int. 1992, 41, 1483–1493.
19. 2 Production in Patients with Systemic Lupus Erythematosus. J. Clin. Invest. 1985, 76, 1011–1018.
20. Fujimura, M.; Sasaki, F.; Nakatsumi, Y.; Takahashi, Y.; Hifumi, S.; Taga, K.; Mifune, J.; Tanaka, T.; Matsuda, T. Effecte of thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 1986, 41, 955–959.
21. Suzuki, S.; Sano, K.; Handa, H.; Asano, T.; Tamura, A.; Yonekawa, Y.; Ono, H.; Tachibana, N.; Hanaoka, K. Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol. Res. 1989, 11, 79–88.
22. Ono, Y.; Misawa, K.; Kudoh, M.; Nakagawa, S. Clinical effects of a thromboxane synthetase inhibitor (OKY-046) on diabetic patients: effects of renal function. In Recent Trends in management of diabetes mellitus; Sakamoto, N., Albert, K. G. M. M., Motta, N., Eds.; Elsevier (Biomedical Division): New York, 1987; pp 546–548.
23. 2 synthetase inhibitor in patients with nephrotic syndrome. Clin. Nephrol. 1988, 30, 276–281.
24. 2 biosynthesis in atherosclerosis. Proc. Natl. Acad. Sci. 1988, 85, 4511–4515.
25. 2 Synthesis. Arteriosclerosis 1988, 8, 359–367.
26. 2+ Channel Ligands: Structure-Function Relationships of The 1,4-Dihydropyridines. Med. Res. Rev. 1989, 9 (2), 123–180.
27. 2 Antagonists. Curr. Opin. Ther. Pat. 1991, 1(9), 1343–1373 and references therein.
28. Kato, K.; Ohkawa, S.; Terao, S.; Terashita, Z.; Nishikawa, K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of ω-pyridiylalkenoic acids. J. Med. Chem. 1985, 28, 287–294.
29. 2 Synthase Inhibitors. 5-(3-Pyridylmethyl)-benzofuran-2-carboxylic Acids. J. Med. Chem. 1986, 29, 1461–1468.
30. Meskens, F. A. J. Methods for the Preparation of Acetals from Alcohols or Oxiranes and Carbonyl Compounds. Synthesis 1981, 501.
31. Sircar, I.; Duell, B. L.; Bristol, A.; Weishaar, R. E.; Evans, D. B. Cardiotonic Agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3-pyridine-carbonitriles and Related Compounds. Synthesis and Inotropic Activity. J. Med. Chem. 1987, 30, 1023–1029.
32. Sitkina, L. M.; Simonov, A. M. Khim Geteratsikl. Soedin. Akad. Namk. Latv. SSR 1966, 143;
33. Chem. Abstr. 1966, 65, 13686a.
34. Eisai Co. EP 34577 A2, 1989.
35. Hacksell, U.; Arvidsson, L. E.; Svensson, U.; Nilsson, J. L. G.; Sanchez, D.; Wikström, H.; Lindberg, P.; Hjorth, S.; Carlsson, A. 3-Phenylpiperidines. Central Dopamine-Autoreceptor Stimulating Activity. J. Med. Chem. 1981, 24, 1475–1482.
36. Bossert, F.; Meyer, H.; Wehinger, E. 4-Aryldihydropyridines, a New Class of Highly Active Calcium Antagonists. Angew. Chem., Int. Ed. Engl. 1981, 20, 762–784.
37. Fossheim, R.; Svarteng, K.; Mostad, A.; Romming, C.; Shefter, E.; Triggle, D. J. Crystal Structures and Pharmacological Activity of Calcium Channel Antagonists: 2,6-Dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 3-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine. J. Med. Chem. 1982, 25, 126–131.
38. Rovnyak, G.; Andersen, N.; Gougoutas, J.; Hedberg, A.; Kimball, S. D.; Malley, M.; Moreland, S.; Porubcan, M.; Pudzianowski, A. Studies Directed toward Ascertaining the Active Conformation of 1,4-Dihydropyridine Calcium Entry Blockers. J. Med. Chem. 1988, 31, 936–944.
39. Höltje, H. D.; Marrer, S. Qualitative and quantitative structure-activity relationships for calcium channel modulating 1,4-dihydropyridine derivatives: a hypothetical molecular receptor model. Quant. Struct.-Act. Rel. 1988, 7, 174–8.
40. Rovnyak, G.; Andersen, N.; Gougoutas, J.; Hedberg, A.; Kimball, S. D.; Malley, M.; Moreland, S.; Porubcan, M.; Pudzianowski, A. Active Conformation of 1,4-Dihydropyridine Calcium Entry Blockers. Effect of Size of 2-Aryl Substituent on Rotameric Equilibria and Receptor Binding. J. Med. Chem. 1991, 34, 2521–2524.
41. Ennis, C.; Granger, S. E.; Middlefell, V. C.; Philpot, M. E.; Shepperson, N. B. Pharmacologic Effects of Wy 27569: A Combined Calcium Channel Blocker And Thromboxane Synthetase Inhibitor. J. Cardiovasc. Pharmacol. 1989, 13, 511–519.
42. Cross, P. E.; Dickinson, R. P.; Parry, M. J.; Randall, M. J. Selective Thromboxane Synthetase Inhibitors. 1-[(Aryloxy)alkyl]-1H-imidazoles. J. Med. Chem. 1985, 28, 1427–1432.
43. Stewart, J. J. MOPAC: A semiempirical molecular orbital program. J. Comp.-Aided Mol. Des. 1990, 4, 1–105.
44. Allen, F. H.; Davies, J. E.; Galloy, J. J.; Johnson, O.; Kennard, O.; Macrae, C. F.; Mitchell, G. F.; Smith, J. M.; Watson, D. G. The development of versions 3 and 4 of the Cambridge Structural Database System. J. Chem. Inf. Comput. Sci. 1991, 31, 187–204.
45. Snedecor, G. W.; Cochran, W. G. Statistical Methods, 6th ed.; The Iowa University Press: Ames, IA, 1974.
46. Patrignani, P.; Filabozzi, P.; Catella, F.; Pugliese, F.; Patrono, C. Differential Effects of Dazoxiben, a Selective Thromboxane-Synthase Inhibitor, on Platelet and Renal Prostaglandin-Endoperoxide Metabolism. J. Pharmacol. Exp. Ther. 1984, 228(2), 472–477.